Anilino-(2-bromophenyl) acetonitrile: A promising orally effective antileishmanial agent

Acta Tropica

Volumn 84, Issue 3, 2002, Pages 165-173

  Gupta, Suman ^a   Tiwari, Suman ^a   Bhaduri, A P ^a   Jain, G K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anti leishmanials; Chemotherapy; Hamster; In vitro; In vivo; Kala azar; Leishmania donovani; Visceral leishmaniasis

Indexed keywords

(2 ACETYLANILINO)(PHENYL)ACETONITRILE; (3 METHOXYANILINO)(PHENYL)ACETONITRILE; (4 BROMOANILINO)(4 CHLOROPHENYL)ACETONITRILE; (4 BROMOANILINO)(4 METHOXYPHENYL)ACETONITRILE; (4 BROMOANILINO)(4 METHYLPHENYL)ACETONITRILE; (4 BROMOANILINO)(PHENYL)ACETONITRILE; ANILINO(2 BROMOPHENYL)ACETONITRILE; ANILINO(2 CHLOROPHENYL)ACETONITRILE; ANILINO(3 BROMOPHENYL)ACETONITRILE; ANILINO(3 CHLOROPHENYL)ACETONITRILE; ANILINO(3 FLUOROPHENYL)ACETONITRILE; ANILINO(3,4 DICHLOROPHENYL)ACETONITRILE; ANILINO(4 CHLOROPHENYL)ACETONITRILE; ANILINO(4 DIMETHYLAMINOPHENYL)ACETONITRILE; ANILINO(4 METHYLPHENYL)ACETONITRILE; ANILINO(PHENYL)ACETONITRILE; ANTILEISHMANIAL AGENT; UNCLASSIFIED DRUG;

DISEASE CONTROL; DRUG DEVELOPMENT; LEISHMANIASIS;

AMASTIGOTE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; DRUG TOLERANCE; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; LD 50; LEISHMANIA DONOVANI; MALE; MOUSE; NONHUMAN; PROMASTIGOTE; VISCERAL LEISHMANIASIS;

ACETONITRILES; ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LETHAL DOSE 50; MALE; MESOCRICETUS; TREATMENT OUTCOME;

CRICETINAE; LEISHMANIA DONOVANI; NASO HEXACANTHUS; PROTOZOA;

EID: 0036890362     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(02)00180-8     Document Type: Article

References (22)

1. Alvar J., Gutierrez-Solar B., Pachon I., Calbacho E., Ramirez M., Valles R., Guillen J., Conavate C., Amela C. AIDS and L. infantum: new approaches for a new epidemiological problem. Clin. Parasitol. 14:1996;541.
2. Anon, 1996. World Health Organization. Inf. Circ. WHO Mediterr. Zoon Control. Cent. 40, 11.
3. Anon, 1998. Tropical Diseases Research Progress 1997-1998, Fourteenth Programme Report - Leishmaniasis, pp. 1-22.
4. Anon, 1999a. TDR/WHO Sponsored Meeting on VL Control, Varanasi, India, 12-14 January.
5. Anon, 1999b. Leishmania/HIV Co-infection, South Western Europe, 1990098. Weekly Epidemiological Record No. 44, 5th November World Health Organisation, pp. 365-375.
6. Basil B. Statistical evaluation in chemotherapy. Schnizer R.J., Hawking F., Experimental Chemotherapy. 1:1963;55-79 Academic Press, New York, London.
7. Beveridge E. Chemotherapy of leishmaniasis. Schnitzer R.J., Hawking F., Experimental Chemotherapy. 1:1963;257-280 Academic Press, New York, London.
8. Bhatnagar S., Guru P.Y., Katiyar J.C., Srivastava R., Mukherjee A., Akhtar M.S., Seth M., Bhaduri A.P. Exploration of antileishmanial activity in heterocycles: results of their in vivo and in vitro bioevaluations. Ind. J. Med. Res. 89:1989;439.
9. Boelaert M., Criel B., Leeuwenburg J., Van Damme W., Le Ray D., Van der Stuyft P. Visceral leishmaniasis control: a public health perspective. Trans. R. Soc. Trop. Med. Hyg. 94:2000;465-471.
10. Bushby S.R.M. Toxicity in chemotherapy. Schnitzer R.J., Hawking F., Experimental Chemotherapy. 1:1963;25-53 Academic Press, New York, London.
11. Gibson D.W., Connor D.M., Brown H.L., Fuhlsang H., Anderson J., Dube B.O.L., Buck A.A. Onchocercal dermatitis - ultrastructural studies of microfilarial and host tissue, before and after the treatment with diethylcarbamazine (hetrazan). Am. J. Trop. Med. Hyg. 25:1976;74-87.
12. Gupta S., Tiwari S., Bagchi A.K., Katiyar J.C. A rising trend in kala-azar in Varanasi district, Uttar Pradesh, India: a recent survey using direct agglutination test. Curr. Sci. 73:1997;456-459.
13. Jha T.K., Giri Y.N., Singh T.K., Jha S. Use of amphotericin B in drug resistant cases of visceral leishmanaisis in north Bihar, India. Am. J. Trop. Med. Hyg. 52:1995;536-538.
14. Jha T.K., Olliaro P., Thakur C.P., Kanyok T.P., Singhania B.L., Singh I.J., Singh N.K.P., Akhonry S., Jha S. Randomized controlled trial of aminosidine (Paramomycin) V. Sodium stibogluconate for treating visceral leishmaniasis in north Bihar, India. Br. Med. J. ii:1998;1200.
15. Kumar R., Kumar P., Chaudhari R.K., Pai K., Mishra C.P., Kumar K., Pandey H.P., Singh V.P., Sundar S. Kala-azar epidemic in Varanasi district, India. Bull. W.H.O. 77:1999;371.
16. Neal R.A., Croft S.L. An in vitro system for determining the activity of compounds against intracellular amastigote forms of Leishmania donovani. J. Antimicrob. Chemother. 14:1984;463.
17. Sundar, S., Singh, V.P., Sharma, S., Makharia, M.K., Murray, H.W., 1997. Response to interferon-plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 126, 1117.
18. Sundar S., Goyal A.K., More D.K., Singh M.K., Murray H.W. Treatment of antimony - unresponsive Indian visceral leishmaniasis with ultrashort courses of amphotericin-B lipid complex. Ann. Trop. Med. Parasitol. 92:(7):1998;755.
19. Sundar S., Gupta L.B., Makharia M.K., Singh M.K., Vors A., Rosenkaimer F., Engel J., Murray H.W. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 93:(6):1999;589.
20. Thakur C.P. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans. R. Soc. Trop. Med. Hyg. 78:1984;391.
21. Thakur, C.P., Sinha, G.P., Barat, D., Singh, R.K., 1994. Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis. Ann. Trop. Med. Parasitol., Vol. 88, 365.
22. Thakur C.P., Sinha G.P., Pandey A.K., Kumar N., Kumar P., Hassan S.M., Narain S., Roy R.K. Do the diminishing efficacy and increasing toxicity of sodium stibogluate in the treatment of VL in Bihar, India, justify its continued use as a first line drug. An observational study of 80 cases. Ann. Trop. Med. Parasitol. 92:(5):1998;561.